Hereditary haemorrhagic telangiectasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hereditary haemorrhagic telangiectasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of ALN-6400 Safety and Effectiveness in Adults with Hereditary Hemorrhagic Telangiectasia https://clinicaltrials.eu/trial/a-study-of-aln-6400-safety-and-effectiveness-in-adults-with-hereditary-hemorrhagic-telangiectasia/ Wed, 29 Apr 2026 15:07:56 +0000 https://clinicaltrials.eu/trial/a-study-of-aln-6400-safety-and-effectiveness-in-adults-with-hereditary-hemorrhagic-telangiectasia/ This study involves healthy adult volunteers and patients with Hereditary Hemorrhagic Telangiectasia, a condition where blood vessels do not form properly, leading to frequent nosebleeds and other bleeding problems. The study will test a treatment called ALN-6400, which is given as an injection under the skin. Some participants will receive ALN-6400 while others will receive placebo or phosphate-buffered saline, which is a salt water solution. The main goal of the study is to evaluate the safety and how well the body tolerates multiple doses of ALN-6400 in adult patients with this bleeding disorder.

The study is divided into two parts. The first part will test a single dose in healthy volunteers to understand how the body processes the medication and to check for any side effects. The second part will give multiple doses to patients who have been diagnosed with Hereditary Hemorrhagic Telangiectasia and experience moderate to severe nosebleeds. Patients in this part must have a history of frequent nosebleeds and may also have low levels of iron in their blood, requiring iron treatments or blood transfusions. During the study, researchers will monitor safety through physical examinations, heart tracings, and blood tests.

Throughout the study, researchers will measure changes in nosebleed frequency, duration, and severity using patient diaries and scoring systems. They will also track changes in blood protein levels, iron levels, and the need for iron infusions or blood transfusions. Quality of life will be assessed using questionnaires to understand how the treatment affects daily activities and breathing through the nose. The study will last several years and includes follow-up periods to continue monitoring the effects of the treatment over time.

]]> Study on the Effectiveness of Nintedanib for Treating Nosebleeds in Patients with Hereditary Hemorrhagic Telangiectasia https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-nintedanib-for-treating-nosebleeds-in-patients-with-hereditary-hemorrhagic-telangiectasia/ Wed, 29 Apr 2026 15:04:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-nintedanib-for-treating-nosebleeds-in-patients-with-hereditary-hemorrhagic-telangiectasia/ This clinical trial is focused on studying the effectiveness of a medication called nintedanib for treating a condition known as hereditary hemorrhagic telangiectasia (HHT). HHT is a genetic disorder that affects blood vessels and can lead to frequent nosebleeds, known medically as epistaxis. The study aims to determine if patients with HHT experience a significant reduction in the duration of their nosebleeds when treated with nintedanib compared to those receiving a placebo.

Participants in the study will be randomly assigned to receive either nintedanib, which is also known by its code name BIBF 1120, or a placebo. The medication is administered in the form of soft capsules taken orally. The study will last for a total of 16 weeks, during which the duration of nosebleeds will be monitored and compared to the baseline period before the treatment started. The goal is to see if there is at least a 30% reduction in the duration of nosebleeds in those taking nintedanib.

The trial is designed to provide valuable information on whether nintedanib can effectively reduce the frequency and duration of nosebleeds in patients with HHT. This could potentially lead to improved management of the condition and better quality of life for those affected. The study will help determine if nintedanib is a viable treatment option for this specific aspect of HHT.

]]>